CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience

BACKGROUND: Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache free days...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheffler, Armin, Schenk, Hannah, Wurthmann, Sebastian, Nsaka, Michael, Kleinschnitz, Christoph, Glas, Martin, Holle, Dagny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454157/
https://www.ncbi.nlm.nih.gov/pubmed/34544359
http://dx.doi.org/10.1186/s10194-021-01323-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454157/
https://www.ncbi.nlm.nih.gov/pubmed/34544359
http://dx.doi.org/10.1186/s10194-021-01323-6

Ejemplares similares